Haleos Labs Limited has officially updated its contact details following the company's name change from SMS Lifesciences India Limited. The company informed BSE Limited and National Stock Exchange of India Limited on March 30, 2026, about the updated email IDs and website address under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Updated Contact Details

The company has implemented new official contact information to align with its rebranded identity:

Background of Name Change

The contact detail updates are consequent to the company's name change from SMS Lifesciences India Limited to Haleos Labs Limited. This transformation received approval through postal ballot with results declared on August 1, 2025. The Ministry of Corporate Affairs subsequently issued a fresh Certificate of Incorporation on August 21, 2025.

The stock exchanges also implemented corresponding changes, with the National Stock Exchange of India Limited issuing Circular No. NSE/LIST/373 and BSE Limited issuing Notice No. 20251120-43 on November 20, 2025, incorporating the new scrip ID HALEOSLABS.

Shareholder Communication

Haleos Labs Limited dispatched communications to its physical shareholders on March 30, 2026, informing them about the updated contact details. The company emphasized that the name change does not alter its legal status in any manner, with the Corporate Identification Number and all other legal identities remaining unchanged.

Company Operations

The company clarified that there is no impact on day-to-day operations due to these changes. All official communications and disclosures have been updated to reflect the new contact information. The company continues to operate from its registered and corporate office at Plot No. 19-III, Road No. 71, Jubilee Hills, Hyderabad.

Haleos Labs Limited has issued an official postal ballot notice seeking shareholder approval for a material related party transaction involving the issuance of a corporate guarantee. The company will conduct the voting process exclusively through electronic means, with the cut-off date scheduled for March 27, 2026.

Transaction Details and Resolution

The postal ballot addresses a single ordinary resolution for approving a material related party transaction. The resolution seeks approval for issuing a corporate guarantee in favour of RBL Bank Limited to secure an External Commercial Borrowing facility availed by Mahi Drugs Private Limited, the company's material subsidiary.

E-Voting Timeline and Process

The company has established a comprehensive timeline for the postal ballot process. Shareholders whose names appear in the Register of Members or List of Beneficial Owners as on the cut-off date will be entitled to vote through remote e-voting only.

Appointed Officials and Agencies

The Board of Directors has appointed key officials to facilitate the postal ballot process. Mr. C. Sudhir Babu (FCS No.7666), a practicing company secretary, has been designated as the scrutinizer to conduct the postal ballot and e-voting process. Central Depository Services (India) Limited has been appointed as the authorized agency to provide the remote e-voting platform to all members.

Related Party Transaction Analysis

The transaction qualifies as a material related party transaction under SEBI regulations. The guarantee amount represents 5.80% of the company's annual consolidated turnover of ₹344.72 crores and 47.31% of Mahi Drugs' annual standalone turnover of ₹42.27 crores.

Regulatory Compliance and Justification

The postal ballot process is being conducted in accordance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company has justified the transaction as commercially prudent, enabling the subsidiary to secure funding at competitive terms and strengthening its financial position. Mahi Drugs has obtained a credit rating of IVR BB+ with stable outlook from Infomerics Valuation and Rating Limited.